Measuring Tryptase Levels in Patients with Stable Coronary Artery Disease
Investigation of the Role and Prognostic Value of Tryptase in Patients With Stable Coronary Artery Disease
This study is testing if measuring tryptase levels in people with stable coronary artery disease can help predict their risk of having serious heart problems in the future.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | University of Thessaly Academic / other |
| Locations | 2 sites (Athens, Attica and 1 other locations) |
| Trial ID | NCT06958016 on ClinicalTrials.gov |
What this trial studies
This observational study aims to measure serum tryptase levels in patients with stable coronary artery disease (CAD) and correlate these levels with the severity of their condition. It will investigate the potential of tryptase as a prognostic biomarker for predicting future cardiovascular events, particularly the transition from chronic coronary syndrome (CCS) to acute coronary syndrome (ACS). The study focuses on the role of mast cell activation in plaque instability, which may contribute to sudden cardiovascular events in patients with CCS. By analyzing the relationship between tryptase levels and cardiovascular health, the study seeks to enhance understanding of CAD progression.
Who should consider this trial
Good fit: Ideal candidates are males and females aged 18 to 85 with clinical symptoms of angina and a positive SPECT scan for myocardial ischemia.
Not a fit: Patients with acute coronary syndrome, recent coronary interventions, or certain medical conditions such as autoimmune diseases or cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new biomarker for predicting cardiovascular events in patients with chronic coronary syndrome.
How similar studies have performed: Previous studies have indicated a potential link between tryptase levels and coronary artery disease, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female subjects aged 18 - 85 years old. * Clinical symptoms of angina which are classified based on the Canadian Cardiovascular Score (CCS score) * Positive SPECT scan for myocardial ischemia Exclusion Criteria: * Acute Coronary Syndrome 4 weeks before the coronary catheterization * Percutaneous Coronary Angioplasty * Coronary Artery Bypass Graft * Active symptoms of allergy (asthma, urticaria) * Mastocytosis * Hypereosinophilia * Autoimmune disease * Cancer * Kidney failure * Myelodysplastic Syndrome * Denial of signing informed consent
Where this trial is running
Athens, Attica and 1 other locations
- 417 Military Hospital NIMTS — Athens, Attica, Greece (Recruiting)
- Larisa University Hospital — Larissa, Thessaly, Greece (Recruiting)
Study contacts
- Study coordinator: Fotios Skoufis, MD Medicine
- Email: fskoufis@hotmail.com
- Phone: +306981088650
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.